Alimera Sciences (NASDAQ:ALIM) Rating Reiterated by HC Wainwright

Alimera Sciences (NASDAQ:ALIM)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Thursday, TipRanks reports. They currently have a $12.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 150.00% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. Alliance Global Partners dropped their price objective on shares of Alimera Sciences from $16.50 to $14.50 and set a “buy” rating for the company in a research note on Tuesday, August 17th. Zacks Investment Research downgraded shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Monday, August 16th.

ALIM traded up $0.44 on Thursday, reaching $4.80. The company had a trading volume of 900 shares, compared to its average volume of 53,978. Alimera Sciences has a fifty-two week low of $3.82 and a fifty-two week high of $12.25. The stock has a market cap of $33.24 million, a P/E ratio of 48.00 and a beta of 1.61. The company’s fifty day moving average is $5.53 and its 200 day moving average is $8.17.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Friday, August 13th. The biopharmaceutical company reported $0.76 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.25 by ($0.49). Alimera Sciences had a negative return on equity of 1.30% and a net margin of 3.92%. The business had revenue of $21.70 million for the quarter, compared to analyst estimates of $23.30 million. Research analysts forecast that Alimera Sciences will post -0.59 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the company. Cooper Creek Partners Management LLC acquired a new stake in Alimera Sciences in the first quarter worth $367,000. Dimensional Fund Advisors LP bought a new stake in Alimera Sciences in the second quarter worth about $260,000. Diametric Capital LP bought a new stake in Alimera Sciences in the first quarter worth about $253,000. Vanguard Group Inc. raised its position in Alimera Sciences by 16.6% in the second quarter. Vanguard Group Inc. now owns 146,863 shares of the biopharmaceutical company’s stock worth $1,336,000 after acquiring an additional 20,905 shares during the period. Finally, Perritt Capital Management Inc. bought a new stake in Alimera Sciences in the first quarter worth about $192,000. 29.20% of the stock is owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.

Featured Story: What economic reports are most valuable to investors?

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.